

ICMJE DISCLOSURE FORM

Date: 12th April 2021

Your Name: Ravi Velaga

Manuscript Title: Advances in molecular medicine for breast cancer practice: A narrative review

Manuscript number (if known): ABS-21-64

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<input checked="" type="checkbox"/> None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input checked="" type="checkbox"/> None	
3	Royalties or licenses	<input checked="" type="checkbox"/> None	
4	Consulting fees	<input checked="" type="checkbox"/> None	
5	Payment or honoraria for lectures, presentations, speakers bureaus,	<input checked="" type="checkbox"/> None	

	manuscript writing or educational events		
6	Payment for expert testimony	<input checked="" type="checkbox"/> <input type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> <input type="checkbox"/> None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> <input type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> <input type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> <input type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> <input type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> <input type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> <input type="checkbox"/> None	

Please summarize the above conflict of interest in the following box:

None

Please place an “X” next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 12th April 2021

Your Name: Masakazu Toi

Manuscript Title: Advances in molecular medicine for breast cancer practice: A narrative review

Manuscript number (if known): ABS-21-64

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<input checked="" type="checkbox"/> None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	Chugai, Takeda, Pfizer	Research grant
		Kyowa-Kirin, Taiho, JBCRG association, Eisai, Daiichi-Sankyo, AstraZeneca, Astellas, Shimadzu, Yakult, Luxonus, AFI technologies, Nippon-Kayaku, Shionogi, GL Science	Research grant
3	Royalties or licenses	<input checked="" type="checkbox"/> None	
4	Consulting fees	Kyowa-Kirin	

		Daiichi-Sankyo	
		AstraZeneca, BMS, Eli Lilly, Athenex Oncology, Bertis, Terumo, Luxonus, Kansai Medical Net	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Takeda, Chugai, Pfizer,	Lecture fee
		Kyowa-Kirin, Taiho,	Lecture fee
		Eisai, Daiichi-Sankyo, Eli Lilly, AstraZeneca, Exact Science, Novartis, Konica Minolta, Shimadzu, Yakult, Nippon Kayaku,	Lecture fee
6	Payment for expert testimony	<u> </u> X <u> </u> None	
7	Support for attending meetings and/or travel	<u> </u> X <u> </u> None	
8	Patents planned, issued or pending	<u> </u> X <u> </u> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u> </u> X <u> </u> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	JBCRG association	Member of board of directors
		KBCRN	Member of board of directors
		OOTR	Member of board of directors
11	Stock or stock options	<u> </u> X <u> </u> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u> </u> X <u> </u> None	
13	Other financial or non-financial interests	<u> </u> X <u> </u> None	

Please summarize the above conflict of interest in the following box:

Prof Dr Toi is supported by the above mentioned grants from Chugai, Takeda, Pfizer, Kyowa-Kirin, Taiho, JBCRG association, Eisai, Daiichi-Sankyo, AstraZeneca, Astellas, Shimadzu, Yakult, Luxonus, AFI technologies, Nippon-Kayaku, Shionogi, GL Science, receives consulting fees from Kyowa-Kirin, Daiichi-Sankyo, AstraZeneca, BMS, Eli Lilly, Athenex Oncology, Bertis, Terumo, Luxonus, Kansai Medical Net, lecture fee from Takeda, Chugai, Pfizer, Kyowa-Kirin, Taiho, Eisai, Daiichi-Sankyo, Eli Lilly, AstraZeneca, Exact Science, Novartis, Konica Minolta, Shimadzu, Yakult, Nippon Kayaku, holds leadership roles at JBCRG, JBCRN & OOTR.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.